Pharmacelsus' GLP implementation exemplary for European CROs

Scientists of the European Center for Validation of Alternative Methods (ECVAM) attended a GLP workshop at Pharmacelsus GmbH

Saarbrücken, 4. Juni 2009 - Pharmacelsus, a CRO specialized in preclinical test services, obtained GLP-certification covering the complete portfolio in November 2008. The company is not only able to perform accompanying analytical services for clinical studies in addition to its preclinical services, but also decided to share its knowledge on the GLP implementation process with other laboratories. Thirteen scientists of the European Commission Joint Research Center came to learn more about Pharmacelsus' solution for the implementation of a GLP system in an /in vitro/ laboratory. During a three days hands-on training, they glanced at the lab-life in theory and practice, especially focusing the GLP relevant implementation on /in vitro/ toxicology and bioanalytics. The practical course provided the opportunity for staff of all levels to understand the importance and relevance of GLP compliance, and how to apply the requirements of GLP into their everyday work in an /in vitro/ laboratory.

Pharmacelsus cooperates with ECVAM in the framework of an international pre-validation study in the field of human metabolism and toxicity which is supervised by ECVAM.

Pharmacelsus offers a wide range of biological, analytical and pharmacological studies for pharmaceutical and biotechnological companies with a focus on preclinical test services. Pharmacelsus holds the statement of GLP compliance for categories 2 (toxicity studies), 8 (analytical and clinical chemistry testing) and 9 (other studies: pharmacodynamic, pharmacokinetic, metabolical and toxicological testing). Because of the GLP status, the company is now able to perform accompanying analytical services for clinical studies in addition to its preclinical services.

Pressekontakt: Kontakt:

Dr. Stefanie Becker Pharmacelsus GmbH
Business Development / Sales Manager Science Park 2

Telefon: +49 (0)681 / 39 46 - 75 16 66123 Saarbrücken
Telefax: +49 (0)681 / 39 46 - 75 11 Telefon: +49 (0)681 / 39 46 - 75 10

E-Mail: becker@pharmacelsus.de
E-Mail: info@pharmacelsus.de

Internet: www.pharmacelsus.de

This announcement is originally distributed by Hugin.
The issuer is solely responsible for the content of this announcement.

This release was published on openPR.